BPH vs. Prostate Cancer: Key Differences & When to Worry
- BPH vs. prostate cancer – the fundamental difference
- Symptom comparison – overlapping vs. distinguishing features
- PSA differences – typical ranges, velocity, density, free PSA
- DRE findings – smooth vs. hard, symmetric vs. nodular
- Risk factors – age, family history, race
- Does BPH turn into prostate cancer? (No)
- Can you have both BPH and prostate cancer?
- Diagnostic tests – MRI, biopsy
- When to worry – red flags for cancer
- Comparison table – BPH vs. prostate cancer
- Interactive FAQ – 9 questions about BPH vs. cancer
BPH vs. prostate cancer – the fundamental difference
BPH (Benign Prostatic Hyperplasia) and prostate cancer are two very different conditions that affect the same gland. The fundamental difference:
- BPH: A non-cancerous (benign) enlargement of the prostate. Cells grow but do not invade or spread. BPH is not life-threatening but can cause bothersome urinary symptoms.
- Prostate cancer: A malignant growth where cells grow uncontrollably, can invade nearby tissues (local spread), and metastasise (spread to bones, lymph nodes). Prostate cancer can be fatal if not treated.
Symptom comparison – overlapping vs. distinguishing features
Both BPH and prostate cancer can cause similar urinary symptoms because both can enlarge the prostate and compress the urethra. However, there are important differences:
Overlapping symptoms (can occur in both):
- Weak urinary stream
- Frequent urination (day and night)
- Urgency
- Hesitancy (difficulty starting)
- Feeling of incomplete emptying
Symptoms more suggestive of BPH:
- Gradual onset over years
- Symptoms are often positional (worse when standing, better when sitting)
- No pain (unless complicated by retention or infection)
Symptoms that suggest prostate cancer (especially advanced):
- Early cancer: Often NO symptoms at all – found by PSA screening
- Bone pain: Persistent back, hip, or rib pain (metastases)
- Unexplained weight loss
- Fatigue
- Blood in urine or semen (can also occur with BPH, but less common)
- New-onset erectile dysfunction (if cancer invades nerves)
- Leg swelling or weakness (from spinal cord compression)
PSA differences – typical ranges, velocity, density, free PSA
PSA (prostate-specific antigen) is elevated in both BPH and prostate cancer, but patterns differ:
Typical PSA ranges:
- BPH: Usually 4-10 ng/mL (mild elevation)
- Prostate cancer: Can range from normal (<4) to very high (>20-100+). About 15-20% of prostate cancers have PSA <4 ng/mL.
PSA velocity (rate of change):
- BPH: Slow, steady rise (0.1-0.3 ng/mL per year)
- Prostate cancer: Rapid rise (>0.75 ng/mL per year over 1-2 years) – concerning
PSA density (PSA divided by prostate volume):
- BPH: Low (<0.15 ng/mL/mL) – large prostate, appropriate PSA
- Prostate cancer: High (>0.15) – small prostate, unexpectedly high PSA
Free PSA (% free PSA):
- BPH: High (>25%)
- Prostate cancer: Low (<10-15%)
DRE findings – smooth vs. hard, symmetric vs. nodular
The Digital Rectal Exam (DRE) is a key physical examination that helps distinguish BPH from cancer:
BPH on DRE:
- Consistency: Smooth, rubbery, symmetric
- Shape: Symmetrically enlarged
- Surface: No discrete nodules
- Median sulcus: May be obliterated but still smooth
Prostate cancer on DRE:
- Consistency: Hard, nodular, asymmetric
- Shape: Irregular, loss of normal contour
- Surface: Discrete hard nodule(s)
- Fixation: May feel fixed (immobile) in advanced cases
Risk factors – age, family history, race
BPH risk factors:
- Aging (primary factor – almost all men develop some BPH by age 80)
- Family history (genetic component)
- Obesity and metabolic syndrome
- Sedentary lifestyle
Prostate cancer risk factors:
- Aging (most common after age 65)
- Family history: Father or brother with prostate cancer (2-3x risk)
- Genetic mutations: BRCA2, HOXB13, Lynch syndrome
- African descent: Higher risk, more aggressive disease
- High-fat diet (possible, but evidence mixed)
Note that BPH and prostate cancer share some risk factors (age, genetics), but obesity is a stronger risk factor for BPH than for prostate cancer.
Does BPH turn into prostate cancer? (No)
This is one of the most common and important misconceptions:
- BPH does NOT turn into cancer. They are biologically distinct conditions arising from different cell types and genetic mutations.
- BPH arises from the transitional zone (periurethral area).
- Prostate cancer arises primarily from the peripheral zone (posterior aspect).
- Having BPH does not increase your risk of developing prostate cancer.
- However, both conditions are common in older men, so they can co-exist in the same prostate.
Can you have both BPH and prostate cancer?
Yes – both conditions are common in aging men, so they frequently co-exist:
- Up to 30-40% of men over 70 have both BPH and incidental prostate cancer.
- BPH does not cause cancer, but the same prostate can have both benign hyperplastic nodules and malignant foci.
- Having both can complicate diagnosis because BPH can elevate PSA, potentially masking or mimicking cancer.
- Treatment for one may affect the other (e.g., TURP for BPH does not treat cancer; prostatectomy for cancer removes BPH as well).
Diagnostic tests – MRI, biopsy
When BPH and cancer cannot be distinguished by symptoms, PSA, or DRE, additional tests are needed:
mpMRI (multiparametric MRI):
- Imaging test that detects suspicious prostate lesions.
- PI-RADS score 1-2: Low suspicion for cancer (can often avoid biopsy).
- PI-RADS 4-5: High suspicion – biopsy recommended.
- Also accurately measures prostate volume (useful for PSA density).
Prostate biopsy:
- The only definitive way to diagnose prostate cancer.
- MRI-targeted biopsy (fusion) is more accurate than standard systematic biopsy.
- Not needed for BPH diagnosis – only for cancer suspicion.
Other markers:
- PHI (Prostate Health Index) – more accurate than PSA alone
- 4Kscore – predicts risk of aggressive cancer
- ExoDx, SelectMDx – urine-based molecular tests
When to worry – red flags for cancer
See a urologist promptly if you have:
- PSA >10 ng/mL or rapid PSA rise (velocity >0.75 ng/mL/year)
- Abnormal DRE (hard nodule, asymmetry, fixation)
- Low free PSA (<10-15%) with total PSA 4-10 ng/mL
- Family history of prostate cancer (especially early-onset or multiple relatives)
- Unexplained bone pain, weight loss, or fatigue
- Blood in urine or semen (especially if persistent)
Comparison table – BPH vs. prostate cancer
| Feature | BPH | Prostate Cancer (Early) | Prostate Cancer (Advanced) |
|---|---|---|---|
| Nature | Benign (non-cancerous) | Malignant (cancerous) | Malignant with metastasis |
| Symptoms | Urinary (weak stream, frequency, nocturia) | Usually NONE | Bone pain, weight loss, fatigue |
| PSA level | Usually 4-10 | Variable (can be normal or elevated) | Often >20-100+ |
| PSA velocity | Slow rise (0.1-0.3/year) | May be rapid (>0.75/year) | Rapid rise |
| Free PSA | Usually >25% | Usually <15% | Often <10% |
| DRE finding | Smooth, symmetric, rubbery | Hard nodule or normal | Hard, irregular, fixed |
| Age at onset | Usually >50 | Usually >50 (rarely <40) | Usually >60 |
| Prognosis | Not life-threatening | Excellent survival (near 100% at 5 years) | Variable (depends on response to treatment) |
Interactive FAQ – BPH vs. prostate cancer
No – absolutely not. BPH and prostate cancer are separate conditions. BPH does not become cancer, and having BPH does not increase cancer risk.
You cannot tell from symptoms alone – early cancer has no symptoms, and BPH and advanced cancer can cause similar urinary symptoms. PSA testing and DRE are essential.
No – only 25-35% of elevated PSAs (4-10 ng/mL) are cancer. BPH and prostatitis are more common causes.
Yes – both are common in older men, so they frequently co-exist. Up to 30-40% of men over 70 have both.
A hard, discrete nodule or asymmetry is highly suspicious for cancer (70-80% probability).
PSA >10 ng/mL, rapid rise (>0.75/year), low free PSA (<10-15%), or high PSA density (>0.15).
5-ARIs (finasteride, dutasteride) reduce PSA and may lower cancer risk but can also mask low-grade cancers. They do not increase cancer risk.
Yes – biopsy is the definitive test. It distinguishes benign hyperplastic tissue from malignant cells.
BPH itself does not increase cancer risk, so screening frequency is based on age and family history, not BPH diagnosis.
Disclaimer: This information is for educational purposes. If you have concerns about BPH or prostate cancer, schedule an evaluation with a urologist at Vivekananda Hospital.